Updates in the Use of Targeted Therapies for Gynecologic Cancers
<乌鸦传媒 class="mpt-content-deck">鈥� An ASCO Reading Room selection August 7, 2024This Reading Room is a collaboration between 乌鸦传媒庐 and:
Targeted therapies have changed the treatment landscape in gynecologic cancer. Studies released over the past year have led to the incorporation of immunotherapy (IO) into the treatment for all patients with endometrial and cervical cancers at some point during their disease course.
Poly(ADP-ribose) polymerase (PARP) inhibitors continue to play a role in women with ovarian carcinoma, particularly in homologous repair deficient tumors. Furthermore, the benefit of PARP inhibitors in challenging subgroups continues to be elucidated.
Biomarker identification has led to the approval or compendium listing of several antibody-drug conjugates (ADCs). This review will update on IO, ADCs, and PARP inhibition for the treatment of gynecologic cancers.
Read an interview about the review here.
Read the full article
Updates in the Use of Targeted Therapies for Gynecologic Cancers
Primary Source
ASCO Educational Book
Source Reference: